Abstract
Lipoprotein (a) (Lp[a]) is a variant of low-density lipoprotein (LDL) that has atherogenic characteristics and is a risk factor for atherosclerotic cardiovascular disease and major adverse cardiovascular events. This report aims to raise awareness about the significance of elevated Lp(a) levels in contributing to atherosclerotic cardiovascular disease and major adverse cardiovascular events and to assist nurse practitioners in using evidence-based approaches to lower its levels. We synthesized recommendations for managing elevated Lp(a) concentrations using the Canadian, United States, and European study guidelines. Combining proprotein convertase subtilisin-kexin type 9 inhibitors with lipid-lowering statins is the most effective treatment for lowering the Lp(a) concentration and cardiovascular risk.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
